LP-184 by Starlight Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

LP-184 is under clinical development by Starlight Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC).

MarketingRx roundup: Eli Lilly’s marketing chief at Cannes Lions, Biogen raises more Alzheimer’s awareness

Eli Lilly’s chief corporate brand officer, Lina Polemini, joined two other marketing leaders at Cannes Lions on Monday to talk about what it means to

June 21, 2023

UCSF studies point the way toward continuous care for people with Parkinson’s disease

Two new studies from UC San Francisco are pointing the way toward round-the-clock personalized care for people with Parkinson’s disease through an implanted device that

August 20, 2024

Chat GPT Plus doesn’t outperform conventional methods in diagnosing patients

With hospitals already deploying artificial intelligence to improve patient care, a new study has found that using Chat GPT Plus does not significantly improve the

November 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.